<DOC>
	<DOCNO>NCT00333424</DOCNO>
	<brief_summary>The development safe effective vaccine HIV subject intensive world-wide research . Various approach investigate monkey model human . This randomized , double-blind trial evaluate safety immunogenicity candidate preventative human immunodeficiency virus ( HIV ) vaccine strategy 24 healthy adult Thai volunteer identifiable risk behaviour HIV-1 infection . Volunteers receive three `` prim '' vaccination week 0 , 4 8 ( pHIS-HIV-AE , DNA vector deliver AE clade HIV-1 gene ) . This follow week 12 single `` boost '' vaccination ( rFPV-HIV-AE , non-replicating , recombinant fowlpox virus vector deliver HIV-1 gene ) . Safety immunological monitoring continue 52 week</brief_summary>
	<brief_title>Thai Prophylactic HIV Vaccine Phase I Study</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy volunteer , judge screen physician base medical history , physical examination laboratory result 18 55 year age , inclusive Laboratory blood value within clinically acceptable range Women reproductive potential must negative urine betahuman chorionic gonadotropin ( BHCG ) pregnancy test screen baseline visit Agreement employ barrier contraception 4 week precede entry whole duration study ( 52 week ) Agreement undertake HIV test receive result Provision write informed consent approve Institutional Ethics Committee ( IEC ) . HIV positive HBsAg HCV positive Identifiable risk behaviour HIV infection , define one following : sexual partner HIV positive people individual report unprotected intercourse partner unknown HIV status , partner report high risk HIV infection ( `` high risk HIV infection '' define individual report unprotected anal intercourse ( UAI ) , unprotected intercourse sex worker and/or share inject equipment within 12 month precede trial entry men report UAI male partner unknown status 12 month precede entry study individual 12 month precede entry study diagnose new sexually transmissible infection ( STI ) may acquire anal vaginal intercourse ( receptive insertive ) individual report share inject equipment last 12 month Recipients prior HIV candidate vaccine previous HIV vaccine trial ( apply volunteer receive placebo adjuvant trial ) Recipients live attenuate vaccine within 60 day prior enter study . Whole kill , toxoid subunit vaccine e.g . influenza , pneumococcus , tetanus , hepatitis B exclusionary give least 4 week prior schedule experimental HIV vaccine Known suspect hypersensitivity egg product know history anaphylaxis serious adverse reaction vaccination History serious allergic reaction require hospitalisation emergency medical care ( e.g . StevenJohnson 's syndrome , bronchospasm hypotension ) substance Clinically significant intercurrent illness history clinically significant illness require immunomodulatory ( include corticosteroid ) cytotoxic treatment ( e.g . cancer ) significant disease condition opinion Principal Investigator preclude individual participate study Recipients blood product immunoglobulins within 6 month prior enter study Recipients experimental investigational agent within 30 day prior enter study Recreational and/or therapeutic druguse , opinion Principal Investigator , might compromise volunteer 's participation way Medical psychiatric condition occupational responsibility may preclude compliance protocol Pregnant lactate woman , woman plan become pregnant trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>HIV</keyword>
	<keyword>Human Immunodeficiency Virus</keyword>
	<keyword>Prophylactic vaccine</keyword>
</DOC>